Cosmo NVCMOPF +4.87%82 Dividend Yield % is 2.89% as of Jun. 25, 2026, which is 89% above its 10-year median of 1.53. GuruFocus rates CMOPF with a GF Score™ of 82/100 and a GF Value™ of $54.86 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 516 Drug Manufacturers companies, Cosmo NV ranks better than 63.37% on this metric.
As of today (2026-06-25), the Trailing Annual Dividend Yield of Cosmo NV is 2.89%.
The historical rank and industry rank for Cosmo NV's Dividend Yield % or its related term are showing as below:
CMOPF'
s Dividend Yield % Range Over the Past 10 Years
Min: 0.84 Med: 1.53 Max: 4.03
Current: 2.89
During the past 13 years, the highest Dividend Yield of Cosmo NV was 4.03%. The lowest was 0.84%. And the median was 1.53%.
CMOPF's Dividend Yield % is ranked better than 63.37% of 516
companies
in the Drug Manufacturers industry
Industry Median: 2.005
vs CMOPF: 2.89
During the past 12 months, Cosmo NV's average Dividends Per Share Growth Rate was 2.50% per year.
During the past 3 years, the average Dividends Per Share Growth Rate was 26.80% per year.
During the past 13 years, the highest 3-Year average Dividends Per Share Growth Rate of Cosmo NV was 26.80% per year. The lowest was 13.40% per year. And the median was 20.10% per year.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
The historical data trend for Cosmo NV's Dividend Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CMOPF vs LLY, JNJ, ABBV: Dividend Yield % Comparison
For the Drug Manufacturers - General subindustry, Cosmo NV's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cosmo NV Dividend Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cosmo NV's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Cosmo NV's Dividend Yield % falls into.
Dividend Yield measures how much a company pays out in dividends each year relative to its share price.
Cosmo NV Recent Full-Year* Dividend History
Amount
Ex-date
Record Date
Pay Date
Type
Frequency
Forex Rate
EUR 2.100000
2026-04-24
2026-04-27
2026-05-11
Cash Dividend
annually
EUR:USD 1.169591
* GuruFocus has an internal rule that if the most recent dividend payment frequency is at least 4 times a year, then the full year will be calculated according to the frequency of payment or the one-year time frame, whichever is stricter.
* GuruFocus converts dividend currency to local traded share price currency in order to calculate dividend yield. Please refer to the last column "Forex Rate" in the above table.
Cosmo NV's Trailing Annual Dividend Yield (%) for Today is calculated as
Trailing Annual Dividend Yield
=
Most Recent Full Year Dividend
/
Current Share Price
=
2.4561411
/
85.45
=
2.87 %
Current Share Price is $85.45. Cosmo NV's Dividends per Share for the trailing twelve months (TTM) ended in Today is $2.4561411.
Cosmo NV's Forward Annual Dividend Yield (%) for Today is calculated as
Forward Annual Dividend Yield
=
Forward Full Year Dividend
/
Current Share Price
=
2.4561411
/
85.45
=
2.87 %
Current Share Price is $85.45. Cosmo NV's Dividends per Share for the forward twelve months is calculated as $2.4561411 * 1 = $2.4561411.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cosmo NV (CMOPF) has a Dividend Yield % of 2.89% as of Jun. 25, 2026. Dividend yield is the ratio of company dividends to the share price. View historical data on Cosmo NV and its competitors. This is 89% above median its historical median of 1.53. Over the past decade, Cosmo NV's Dividend Yield % has ranged from 0.84 to 4.03. According to the industry distribution chart, Cosmo NV ranks #189 out of 516 companies in the Drug Manufacturers industry, placing it in the top 36.6%.
Is Cosmo NV's Dividend Yield % too high?
Cosmo NV's current Dividend Yield % of 2.89% is 89% above median its 10-year median of 1.53. Over the past 10 years, this metric has ranged from a low of 0.84 to a high of 4.03. The Drug Manufacturers industry median Dividend Yield % is 2.01. Cosmo NV's value of 2.89% is 44.1% above this industry median. Based on the distribution chart, Cosmo NV ranks #189 out of 516 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Cosmo NV has a GF Score™ of 82/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cosmo NV's Dividend Yield % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Cosmo NV ranks #189 out of 516 companies for Dividend Yield %. This puts Cosmo NV in the upper half of its industry. The industry median Dividend Yield % is 2.01. Cosmo NV's value of 2.89% is 44.1% above this benchmark. Historically, Cosmo NV's own Dividend Yield % has ranged from 0.84 to 4.03 over the past decade. While the company's 10-year median is 1.53 vs. the industry median of 2.01, Cosmo NV has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Yield % for a Drug Manufacturers company?
The median Dividend Yield % among Drug Manufacturers companies is 2.01, based on 516 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cosmo NV's current Dividend Yield % of 2.89% is 44.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Yield % mean?
A high Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Dividend yield is the ratio of company dividends to the share price. View historical data on Cosmo NV and its competitors. For the Drug Manufacturers industry, the median Dividend Yield % is 2.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cosmo NV's current Dividend Yield % is 2.89%, which is 89% above median its own 10-year median of 1.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cosmo NV stock overvalued right now?
Based on GuruFocus' analysis, Cosmo NV (CMOPF) is currently considered Significantly Overvalued. The stock's GF Value™ is $54.86, compared to a current price of $85.45 — trading 55.8% above its estimated fair value. The current Dividend Yield % is 2.89%, which is 89% above median its 10-year median of 1.53 and 44.1% above the Drug Manufacturers industry median of 2.01. Cosmo NV's overall GF Score™ is 82/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Yield % calculated?
Dividend Yield % is calculated from a company's financial statements. For Cosmo NV (CMOPF), the current Dividend Yield % is 2.89% as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cosmo NV (CMOPF) Overvalued in 2026?
Based on GuruFocus' analysis, Cosmo NV stock appears to be overvalued.
The current stock price of $85.45 is trading 55.8% above its estimated GF Value™ of $54.86.
GuruFocus considers Cosmo NV to be Significantly Overvalued.
Key valuation signals for CMOPF:
Dividend Yield %: 2.89% (89% above median its 10-year median of 1.53)
GF Value™: $54.86 vs. price of $85.45 (55.8% above fair value)
Industry Position: 44.1% above the Drug Manufacturers median (#189 of 516)
No single metric tells the full story. See the CMOPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cosmo NV is is a life sciences company. The company is focused on MedTech AI, dermatology, gastrointestinal diseases, and contract development and manufacturing (CDMO). The company designs, develops, and manufactures solutions to address critical medical needs. Its technologies are trusted by international pharmaceutical and MedTech companies and reach patients and healthcare providers around the world. The product pipeline includes Eleview, GI Genius, Winlevi, Lialda, Uceris, and others.
82GF Score
Get the complete analysis for CMOPF
Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CMOPF has been successfully added to your 
